| Species |
Human |
| Protein Construction |
LYPD3 (Leu31-His286)_x000D_
Accession # O95274 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LYPD3, His, Human at 1μg/ml (100μl/Well) on the plate can bind AntiLYPD3 Ab hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
27.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Aberrant expression of LYPD3 plays an oncogenic role in several types of cancer. LYPD3 was highly expressed in LUAD tumor compared with paracancerous tissues.Furthermore, the expression of LYPD3 was able to be regulated by the methylation in LYPD3 promoter region, which was positively associated with the overall survival. LYPD3 might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway. |
| Synonyms |
MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
